## COVID-19 THERAPIES QUICK GUIDE

<table>
<thead>
<tr>
<th>Type of COVID-19 Therapies</th>
<th>Pre-Exposure Prophylaxis</th>
<th>Monoclonal Antibodies</th>
<th>Oral Antivirals</th>
<th>IV Antivirals</th>
</tr>
</thead>
<tbody>
<tr>
<td>What is available</td>
<td>Evusheld</td>
<td>Bebtelovimab</td>
<td>Lagevrio (molnupiravir) Paxlovid</td>
<td>VEKLURY (remdesivir)</td>
</tr>
</tbody>
</table>
| Who is it for?            | Adult and pediatric patients (at least 12 years of age and older weighing at least 40 kg) who:  
  • are not currently infected with SARS-CoV-2 (COVID-19).  
  • have not had a known recent exposure to an individual infected with SARS-CoV-2 (COVID-19).  
  • are moderately to severely immunocompromised.  
  • are not recommended to receive the COVID-19 vaccine.  
  | Adult and pediatric patients (at least 12 years of age and older weighing at least 40 kg) who:  
  • have high risk for progressing to severe COVID-19, including hospitalization or death.  
  | Paxlovid:  
  • Adults and pediatric patients (12 years of age and older weighing at least 40 kg).  
  | Lagevrio:  
  • Adults at high risk for progressing to severe COVID-19, including hospitalization or death.  
  • Adults who are not recommended alternative COVID-19 treatment options or do not have accessibility to other COVID-19 treatment options.  
| When to access?           | 2 weeks after vaccine    | Within 7 days or less after testing positive for COVID-19 | Within 5 days or less after testing positive for COVID-19 | Within 7 days or less after testing positive for COVID-19 |
| How to access?            | Healthcare Providers     | Healthcare Providers | Healthcare Providers, Local pharmacies | Inpatient healthcare facilities |

More information can be found at hhs.gov